Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. - Wikidata - wikimedia - TriplyDB

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

http://www.wikidata.org/entity/Q39692668

about

Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?Biological features and biomarkers in hepatocellular carcinoma Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review Dickkopfs and Wnt/β-catenin signalling in liver cancer Kremen1 and Dickkopf1 control cell survival in a Wnt-independent manner Recent advances in antimultiple myeloma drug development.SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells.p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment DKK-1 in prostate cancer diagnosis and follow up Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype Molecular changes in pre-metastatic lymph nodes of esophageal cancer patients.PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases.SOST Inhibits Prostate Cancer Invasion.Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma.A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting β-catenin/LEF-1 signaling.NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2.The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation.Wnt and Wnt inhibitors in bone metastasis.Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma Wnt/β-catenin Signaling in Normal and Cancer Stem Cells.Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses.Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy.Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma.Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy.CKAP4 is a Dickkopf1 receptor and is involved in tumor progression.Diagnostic investigations of DKK-1 and PDCD5 expression levels as independent prognostic markers of human chondrosarcoma.p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence.Dickkopf-1 is a novel prognostic biomarker for laryngeal squamous cell carcinoma.In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.Molecular mechanisms of sorafenib action in liver cancer cells.

P2860

Q26745556-0848C6F5-559B-4357-BB20-7F3C940EEABC Q26799462-B882F0D0-EA57-4C9A-8CA5-485FE4FE62A2 Q28086989-F43947D1-2676-4499-B989-9CA944F805AA Q28391394-177FE6F5-1587-4187-8862-6D03588C206C Q28975609-47FA014A-F59E-4F08-B38E-1BF0B9EEA7D6 Q33416297-A7C13624-A06B-4F9B-A000-F8ECA3A7088F Q34277248-D8FA8B16-44BF-41B7-AA67-B39D87774169 Q34685574-6C9BC9FC-F67C-4048-8930-C61DBC474B8C Q34978835-C969E814-0D95-4949-AEF4-441A5C7A0E71 Q35127390-11A3DFE6-E400-4954-8C1C-6465FB3195D3 Q35147858-0251509F-FFFD-4436-8866-66BDA461F348 Q35210676-B1EF32B6-690B-4F35-AB99-9A6704E8B1B5 Q35531393-F5F8E3CA-12F2-40AF-9E26-F45996082116 Q35651705-D0FDF77E-FAB5-4FBF-876A-50631FD70B33 Q35768464-ECC87378-AEFF-4CA8-8415-49B09735D434 Q35792851-41D752E6-8156-4FC4-B303-078D2E55D169 Q35834478-04679722-23EC-4A73-B8CC-B090EB154233 Q35971072-912917F4-2068-4B2F-A4EC-DF2D6AB86F1D Q36448890-A8CBCD20-7441-4D37-9FA6-ECF0C5B15CFA Q36544861-9B2C1F9D-3596-48B4-B1B3-9AEF916165AA Q36593998-DCB04152-D21D-4AAA-AD98-48A970EC704E Q37056355-EBA7FCB4-50C9-46A9-B692-20921B7E1D3A Q37094902-FD216F50-3FAA-49AE-AA9A-ADE939730C87 Q37132716-6C95A508-FB5B-4B02-AAE3-6E222DD2FFE1 Q37252155-27FD75DD-BED7-4B8B-BF52-1F70C9FAE3E4 Q37718250-78D3A01E-64AE-45AE-99B3-802FB0C84D2A Q38105238-7C6C5043-C866-4F5C-936E-0F325BA6BBBD Q38127721-E682D328-14B1-40A7-977A-6231AF5BA769 Q38210247-ECE6E116-0617-4886-9D9D-1091123A4FD3 Q38406799-75CF78B2-33E2-404A-ABBA-EC1BC806617B Q38450711-915386CA-AC20-453D-82D7-5158A504846C Q38682748-A78B0A7E-2D64-4E42-8BEA-368CB5E9D436 Q38763359-C88F8B2F-6B4A-4413-85E2-C4E89E286807 Q38766949-7F01C4FA-17EB-47A4-BB46-409DA08630C0 Q38791188-1B3C5DF8-1F69-454F-8BA1-1282B0D5C779 Q38989969-B7EBE911-C2D8-4578-BD26-6BBB51D2E1E6 Q38994435-2E3365A8-7280-454B-ADD4-93598267DAED Q39208071-5FD158A1-9FB9-47B6-820C-901A64B6D55A Q39248557-8ECFABC3-5914-4AAE-BD20-575298281839 Q39313526-A9D295F2-E0C4-4592-AB04-BECA6CFB8DE9

P2860

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

http://www.wikidata.org/entity/Q39692668

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@en

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@nl

type

label

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@en

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@nl

prefLabel

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@en

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@nl

P1433

Q39692668-61104D85-0D2E-4C80-A84E-7A5B8110F731

P1476

Q39692668-5032C711-456C-4BA0-AFF2-144C024D5D98

P2093

Q39692668-159BB827-44E1-4AE0-9363-8A3CBE6158E7

Q39692668-1E8F5AA2-F383-453A-BD6C-22F55FA8CE18

Q39692668-3A2F2442-98E9-42CA-9287-CCFE9C357549

Q39692668-3E7E58DB-20F7-4413-8AAA-4260CB9AB7AA

Q39692668-3EE9A206-DD69-45CF-8636-729C1846BBBA

Q39692668-6322CD5F-944D-46AE-805B-7750AEEDF19D

Q39692668-76065E29-1FB0-450C-8A50-0B2C5C1B48DC

Q39692668-849E88A3-271F-4DE8-B10A-A06765E91060

Q39692668-ACEAE1BD-59C9-4323-8A0E-598421D83A68

Q39692668-AD0421D7-C8BA-4FA7-A0AE-936FE92E4E65

P304

Q39692668-A5EAC134-0637-40B5-A171-C85F27401C11

P31

Q39692668-4E6CE511-3F69-492A-84B6-9597FC5B4F86

P356

Q39692668-1FECFA5C-B6A5-4CF1-B89D-F77A380F502E

P407

Q39692668-3A4E8771-1219-43A2-AB87-7CB9EA671874

P433

Q39692668-89ED390D-ECD6-4560-A14D-D767E8377015

P478

Q39692668-B9DBEBFE-AE4B-4291-AFF4-46FA855FDE1F

P577

Q39692668-916B77C6-2429-4FD7-82D7-728C584961A0

P698

Q39692668-897B5C80-4A30-4B25-9577-2707C495349E

P921

Q39692668-B7CC1315-7D73-41FF-8663-6ABB1BD19278

P356

0008-5472.CAN-09-3879

P1433

Cancer Research

P1476

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.

@en

P2093

Atsushi Takano

http://www.w3.org/2001/XMLSchema#string

Eiju Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Haruhiko Nakayama

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Ito

http://www.w3.org/2001/XMLSchema#string

Junkichi Koinuma

http://www.w3.org/2001/XMLSchema#string

Ken Masuda

http://www.w3.org/2001/XMLSchema#string

Masaki Miyamoto

http://www.w3.org/2001/XMLSchema#string

Masato Aragaki

http://www.w3.org/2001/XMLSchema#string

Nagato Sato

http://www.w3.org/2001/XMLSchema#string

Nobuhisa Ishikawa

http://www.w3.org/2001/XMLSchema#string

P304

5326-5336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-3879

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20551066

http://www.w3.org/2001/XMLSchema#string

P921